In vivo overexpression of synaptogyrin‐3 promotes striatal synaptic dopamine uptake in LRRK2R1441G mutant mouse model of Parkinson's disease
暂无分享,去创建一个
S. Ho | Lingfei Li | S. Pang | D. Ramsden | Hui-Fang Liu | M. Kung | Philip Wing-Lok Ho | E. Chang | Zoe Yuen-Kiu Choi | Yasine Malki | Chi-Ting Leung
[1] S. Ho,et al. Transcriptional Regulation of the Synaptic Vesicle Protein Synaptogyrin-3 (SYNGR3) Gene: The Effects of NURR1 on Its Expression , 2022, International journal of molecular sciences.
[2] D. Denys,et al. Striatal dopamine signals are region specific and temporally stable across action-sequence habit formation , 2022, Current Biology.
[3] Zhen Yan,et al. Transcriptomic analysis of human brains with Alzheimer’s disease reveals the altered expression of synaptic genes linked to cognitive deficits , 2021, Brain communications.
[4] M. Farrer,et al. Dynamic control of the dopamine transporter in neurotransmission and homeostasis , 2021, NPJ Parkinson's disease.
[5] D. Sarkar. A Review of Behavioral Tests to Evaluate Different Types of Anxiety and Anti-anxiety Effects , 2020, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.
[6] J. Kristensen,et al. The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation , 2019, Neuropharmacology.
[7] S. Ho,et al. The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease , 2019, Translational Neurodegeneration.
[8] Jing Wang,et al. Identification of key genes and pathways for Alzheimer’s disease via combined analysis of genome-wide expression profiling in the hippocampus , 2019, Biophysics Reports.
[9] Seth G. N. Grant,et al. Synapse molecular complexity and the plasticity behaviour problem , 2018, Brain and neuroscience advances.
[10] P. Verstreken,et al. Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau , 2018, Neuron.
[11] Kwang-Hyeon Liu,et al. LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT1A Receptor Upregulation in Mice , 2018, The Journal of Neuroscience.
[12] J. Shim,et al. Oxidative stress and cellular pathologies in Parkinson’s disease , 2017, Molecular Brain.
[13] Sohee Jeon,et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease , 2017, Science.
[14] J. Segura-Aguilar,et al. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease? , 2017, ACS chemical neuroscience.
[15] B. Wieringa,et al. The SH-SY5Y cell line in Parkinson’s disease research: a systematic review , 2017, Molecular Neurodegeneration.
[16] S. Ho,et al. Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease , 2017, Scientific Reports.
[17] S. Cragg,et al. Striatal dopamine neurotransmission: regulation of release and uptake. , 2016, Basal ganglia.
[18] E. Fedele,et al. LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex , 2014, Front. Mol. Neurosci..
[19] S. Ho,et al. LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity , 2014, Annals of clinical and translational neurology.
[20] M. Mattson,et al. Communication breakdown: The impact of ageing on synapse structure , 2014, Ageing Research Reviews.
[21] J. Foster,et al. Mechanisms of dopamine transporter regulation in normal and disease states. , 2013, Trends in pharmacological sciences.
[22] Robert E. Burke,et al. Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.
[23] E. Belluzzi,et al. Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2. , 2012, Biochemical Society transactions.
[24] R. Tsien,et al. Synaptic vesicle pools and dynamics. , 2012, Cold Spring Harbor perspectives in biology.
[25] R. Leube,et al. Synaptogyrin-dependent modulation of synaptic neurotransmission in Caenorhabditis elegans , 2011, Neuroscience.
[26] E. Jazin,et al. Age‐related changes in gene expression are accelerated in Alzheimer's disease , 2011, Synapse.
[27] W. Wurst,et al. LRRK2 Controls Synaptic Vesicle Storage and Mobilization within the Recycling Pool , 2011, The Journal of Neuroscience.
[28] M. Askenazi,et al. A QUICK Screen for Lrrk2 Interaction Partners – Leucine-rich Repeat Kinase 2 is Involved in Actin Cytoskeleton Dynamics* , 2010, Molecular & Cellular Proteomics.
[29] R. Burke,et al. Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.
[30] F. Benes,et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. , 2009, Brain : a journal of neurology.
[31] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.
[32] H. Sitte,et al. Physical and Functional Interaction between the Dopamine Transporter and the Synaptic Vesicle Protein Synaptogyrin-3 , 2009, The Journal of Neuroscience.
[33] R. Paylor,et al. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety , 2009, Psychopharmacology.
[34] N. Hattori,et al. LRRK2 regulates synaptic vesicle endocytosis. , 2008, Experimental cell research.
[35] Steven Hahn,et al. Transcriptional regulation , 2008, EMBO reports.
[36] M. Dichter,et al. Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity , 2008, Brain Research.
[37] Y. Sugimoto,et al. Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice. , 2007, Biological & pharmaceutical bulletin.
[38] F. Penault-Llorca,et al. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification , 2007, Breast Cancer Research.
[39] W. Jones,et al. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines , 2006, Laboratory Investigation.
[40] E. Prinssen,et al. A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. , 2006, European journal of pharmacology.
[41] A. Schapira. Non-motor symptoms , 2006 .
[42] V. Sossi,et al. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. , 2006, Brain : a journal of neurology.
[43] A. Beaudet,et al. Normal biogenesis and cycling of empty synaptic vesicles in dopamine neurons of vesicular monoamine transporter 2 knockout mice. , 2004, Molecular biology of the cell.
[44] Howard J Federoff,et al. Dysregulation of Gene Expression in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Mouse Substantia Nigra , 2004, The Journal of Neuroscience.
[45] C. Thaller,et al. Characterization of synaptogyrin 3 as a new synaptic vesicle protein , 2004, The Journal of comparative neurology.
[46] S. Kügler,et al. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area , 2003, Gene Therapy.
[47] S. Ho,et al. The aetiology of idiopathic Parkinson's disease , 2001, Molecular pathology : MP.
[48] S. Amara,et al. The Dopamine Transporter in Mesencephalic Cultures Is Refractory to Physiological Changes in Membrane Voltage , 2001, The Journal of Neuroscience.
[49] Nikolaus R. McFarland,et al. Striatonigrostriatal Pathways in Primates Form an Ascending Spiral from the Shell to the Dorsolateral Striatum , 2000, The Journal of Neuroscience.
[50] T. Südhof,et al. Synaptogyrins Regulate Ca2+-dependent Exocytosis in PC12 Cells* , 1999, The Journal of Biological Chemistry.
[51] B. Roe,et al. Characterization of the human synaptogyrin gene family , 1998, Human Genetics.
[52] Alessandra Valentini,et al. Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour , 1998, Behavioural Brain Research.
[53] James M. Wilson,et al. Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.
[54] Jennifer A. Mangels,et al. A Neostriatal Habit Learning System in Humans , 1996, Science.
[55] I. Gyertyán,et al. Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying , 1995, Behavioural pharmacology.
[56] E. Masliah,et al. Quantitative synaptic alterations in the human neocortex during normal aging , 1993, Neurology.
[57] S. Handley,et al. Evaluation of marble-burying behavior as a model of anxiety , 1991, Pharmacology Biochemistry and Behavior.
[58] J. Volkmann,et al. Parkinson disease , 2017, Nature Reviews Disease Primers.
[59] S. Ho,et al. Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease , 2017, Scientific Reports.
[60] D. Langford,et al. Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. , 2013, Methods in molecular biology.
[61] J. Rawlins,et al. T-maze alternation in the rodent , 2006, Nature Protocols.